Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BNTC logo BNTC
Upturn stock ratingUpturn stock rating
BNTC logo

Benitec Biopharma Ltd ADR (BNTC)

Upturn stock ratingUpturn stock rating
$12.66
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: BNTC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $25.71

1 Year Target Price $25.71

Analysts Price Target For last 52 week
$25.71 Target price
52w Low $8.06
Current$12.66
52w High $17.15

Analysis of Past Performance

Type Stock
Historic Profit -11.31%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 332.33M USD
Price to earnings Ratio -
1Y Target Price 25.71
Price to earnings Ratio -
1Y Target Price 25.71
Volume (30-day avg) 7
Beta 0.4
52 Weeks Range 8.06 - 17.15
Updated Date 08/15/2025
52 Weeks Range 8.06 - 17.15
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.03

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -31.34%
Return on Equity (TTM) -48.57%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 229706937
Price to Sales(TTM) 2770.13
Enterprise Value 229706937
Price to Sales(TTM) 2770.13
Enterprise Value to Revenue 10457.68
Enterprise Value to EBITDA 0.27
Shares Outstanding 26250500
Shares Floating 12567143
Shares Outstanding 26250500
Shares Floating 12567143
Percent Insiders 3.12
Percent Institutions 90.98

ai summary icon Upturn AI SWOT

Benitec Biopharma Ltd ADR

stock logo

Company Overview

overview logo History and Background

Benitec Biopharma Ltd (BNTC) is a biotechnology company focused on the development of novel genetic medicines based on its proprietary DNA-directed RNA interference ('ddRNAi') platform. Founded in 1997, Benitec has aimed to develop innovative therapeutics for chronic and life-threatening human diseases.

business area logo Core Business Areas

  • Gene Therapy: Focuses on developing ddRNAi-based therapies for various diseases, including Oculopharyngeal Muscular Dystrophy (OPMD) and other genetic disorders.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in biotechnology and drug development. The organizational structure includes research and development, clinical operations, and business development departments.

Top Products and Market Share

overview logo Key Offerings

  • BB-301 (for OPMD): BB-301 is Benitec's lead product candidate, a gene therapy treatment for OPMD. It uses ddRNAi to reduce expression of the mutated PABPN1 gene. The market for OPMD treatments is currently underserved. Competitors are generally other companies pursuing gene therapy or alternative treatments for OPMD.

Market Dynamics

industry overview logo Industry Overview

The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increasing regulatory approvals. There's substantial investment and competition in this space.

Positioning

Benitec is positioned as a specialized gene therapy company with a focus on ddRNAi technology. Its competitive advantage lies in the potential of ddRNAi to provide a durable and specific therapeutic effect.

Total Addressable Market (TAM)

The TAM for OPMD and other genetic disorders targeted by Benitec's pipeline is substantial. Benitec's position depends on clinical success and market access.

Upturn SWOT Analysis

Strengths

  • Proprietary ddRNAi technology
  • Lead product candidate in clinical development (BB-301)
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial success
  • Small market capitalization

Opportunities

  • Positive clinical trial data
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas

Threats

  • Clinical trial failures
  • Competition from other gene therapy companies
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • PTCT
  • SRPT
  • CRSP

Competitive Landscape

Benitec faces competition from larger, more established biotechnology and pharmaceutical companies. Its competitive advantage lies in its ddRNAi technology, but it needs to secure funding and demonstrate clinical efficacy to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: Growth has been primarily driven by advancing BB-301 through clinical development.

Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approvals for BB-301 and other pipeline candidates.

Recent Initiatives: Recent initiatives include enrollment in clinical trials for BB-301 and exploration of partnerships.

Summary

Benitec Biopharma is a high-risk, high-reward clinical-stage biotechnology company. Its ddRNAi technology holds promise, but its success hinges on clinical trial outcomes and funding. The company faces significant competition and financial challenges. Positive data from BB-301's clinical trials is essential for future growth and shareholder value. Future growth will also be influenced by any potential collaborations or partnerships formed with larger pharmaceutical companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry News

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Information is based on publicly available data and may be subject to change. Investing in clinical-stage biotechnology companies is highly speculative and involves significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Benitec Biopharma Ltd ADR

Exchange NASDAQ
Headquaters Hayward, CA, United States
IPO Launch date 2015-08-18
Executive Chairman & CEO Dr. Jerel A. Banks M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.